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Fluconazole is an important drug in the treatment of cutaneous and systemic mycoses. The Hospital de Clínicas de Porto Alegre 
performs a derivation of fluconazole capsules to obtain an oral liquid formulation that is easily administered and whose dose can be 
adjusted. In order to replace the derivation for a formulation produced from an active pharmaceutical ingredient, this study sought 
to develop a liquid oral formulation, evaluate its physical chemical and microbiological stability and demonstrate suitability of the 
analytical method for the formulation assay. Seven different formulations of pharmaceutical suspension form were produced and 
evaluated for pH, viscosity, sedimentation volume and assay. The analytical method by High Performance Liquid Chromatography 
was demonstrated. Two most promising formulations were manipulated in the Farmácia Semi-Industrial do Hospital de Clínicas 
de Porto Alegre and stored in amber PET bottles under three different conditions: room temperature, under refrigeration (2 to 8 ºC) 
and in an oven (40 ° C). Samples were collected after 0, 7 and 14 days to evaluate physical-chemical stability, assay, pH and 
macroscopic aspects. Samples were collected after 0 and 21 days to evaluate microbiological stability. It was possible to demonstrate 
stability for one of the formulations for a 14-day period. Throughout the study, the chosen formulation presented adequate 
quantification of fluconazole, constant pH, no organoleptic changes and no microbial growth. The results suggest the incorporation 
of a new formulation for fluconazole to the Farmacia Semi-Industrial portfolio). 
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Introduction 
 
Fluconazole is a triazole antifungal drug, one of the most 
important drug classes used in cutaneous and systemic 
mycoses treatment1. Triazoles act by inhibiting ergosterol 
synthesis, an important fungal cell membrane component. 
Fluconazole has a broad spectrum of activity and is used to 
treat infections like candidiasis and cryptococcal meningitis. 
It is especially useful in transplanted patients’ prophylactic 
treatment and to fight infections in immunosuppressed 
patients 2, 3, 4, 5, 6. 
The Hospital de Clínicas de Porto Alegre has many patients 
with needs for specific medications, such as pediatric 
patients, transplanted patients and patients using catheters, 
drains and tubes. To treat those cases, the Farmácia Semi-
Industrial (FSI) performs manipulations or pharmaceutical 
derivations. Formulation stability studies are necessary to 
look at the best way of preparation, the package to be used, 
storage conditions and expiration date.7, 8. Fluconazole oral 
suspension is among the FSI’s products. 
Most of the medications are available in solid dosage form, 
which is not  the most appropriate form to be considered for 
patients with specific administration and dosage needs 
(pediatric and transplanted patients, for example) 9, 10. One 
alternative is the oral administration of parenteral 
formulations, but their concentrations demand dilution and 
manipulation, which can make de final volume unfeasible for 
oral administration 11, 12. This can be solved by preparing oral 
solutions or suspensions from solid forms or even from the 
active pharmaceutical ingredient itself 13. In order to facilitate 
the administration of fluconazole to patients admitted to the 
hospital, the present study sought to prepare a fluconazole 
liquid oral formulation, in the pharmaceutical suspension 
form. We also attempted to verify the suitability of a 
compendial analytical method for the quantitative 
determination of fluconazole in the developed suspension and 
to evaluate its physical-chemical and microbiological 
stability to propose a safe time interval for its use. 
 
Materials and methods 
 
Reagents: Purified water, Direct-Q3UV, Millipore®; 
Potassium phosphate monobasic, Merck®; Methanol for 
liquid chromatography, LiChrpsolv®; Acetonitrile for liquid 
chromatography, Vetec ®; Fluconazole standard substance, 
declared content of 100.9% (LAPPS-Faculdade de 
Farmácia/UFRGS)  
 
Pharmaceutical ingredients: Fluconazole active 
pharmaceutical ingredient, Delaware ®, declared content of 
99.68%, Batch 1007/17; Carboxymethylcellulose, Delaware 
®, batch 1006/16; Simple Syrup, FSI/HCPA, Batch 002/18; 
Glycerin, Rioquímica ®, Batch 1701655; Propyleneglycol, 
Rioquímica ®, Batch 1512043.  
  
Formulation Development 
Seven fluconazole suspensions of 50 mg/mL were 
manipulated and evaluated for pH, viscosity and 
sedimentation volume. The composition for each formulation 
is shown in Table 1. For all formulations, fluconazole was 
previously ground in a mortar and levigated with glycerin or 
propyleneglycol. HANNA Instruments pH21 model pH 
meter was used to determinate the pH of the formulations. 
Viscosity was measured using a model RDVD-1 + Brookfield 
Viscosimeter with a nº 4 spindle at 100 rpm. The 
sedimentation volume was calculated (Equation 1) and the 
volume of formed sediment was measured in a graduated 
cylinder 1, 2, 24, 48, 72 and 168 hours after resuspension.  
 
Drug Anal. Res., v. 4, n. 1, p. 39-43, 2020 
40 
 
 
 
 
 
Table 1 – Fluconazole suspensions content. 
Formulation Fluconazole Glycerin PPG1 CMC2 Simple 
Syrup 
1 5 g - - - qs 100 mL 
2 5 g 10 mL - - qs 100 mL 
3 5 g - 10 mL - qs 100 mL 
4 5 g 10 mL - qs 100 mL - 
5 5 g 10 mL - 40 mL qs 100 mL 
6 5 g 10 mL - 25 mL qs 100 mL 
7 5 g 10 mL - 10 mL qs 100 mL 
1Propyleneglycol, 2 Carboxymethylcellulose, 1% aqueous solution. 
 
Analytical Method Suitability 
The compendial method for fluconazole assay in suspension 
recommended by the United States Pharmacopeia 41th 
edition14 was used to evaluate the the quantitative content of 
the formulations. Samples were analyzed on an Agilent High 
Efficiency Liquid Chromatograph, LC 1200 series, equipped 
with quaternary pump (G1311A), autoinjector (G1329A) and 
diode array detector (1315B), using a Zorbax Eclipse Plus 
C18 Agilent® chromatographic column (150 mm x 4.6 mm x 
5 μm). ChemStation software version B03.02 was used for 
data acquisition and analysis of results. The suitability of the 
method was demonstrated by evaluating the following 
parameters. 
 
Selectivity: The chromatograms of Formulation 6 (which 
contains all evaluated excipients) were compared to those of 
a placebo formulation with no active ingredient. 
 
Linearity: 1 mg/mL fluconazole standard stock solution was 
prepared and diluted to reach fluconazole final concentrations 
of 80, 90, 100, 110 and 120 µg/mL. This procedure was 
repeated three times independently.  
 
Precision: Six fluconazole sample solutions at 100 µg/mL 
concentration were prepared. DPR of the six samples was 
used to determine Repeatability. DPR among twelve samples 
prepared on different days by different analysts was used to 
determine intermediate precision. 
 
Accuracy: 100, 110 and 120 µg/mL fluconazole solutions 
were obtained by adding different amounts of 1 mg/mL 
fluconazole standard solution in 1 mg/mL fluconazole sample 
solution. Accuracy was assessed by the recovery in each 
concentration in triplicate. 
 
Stability Study 
The formulations that showed previous results within limits 
established internally were produced on a semi-industrial 
scale and placed in amber PET bottles for the stability study. 
A sample was taken to perform a microbiological test. Five 
bottles of each formulation were stored at room temperature, 
in a refrigerator (2 to 8 ºC) and in an oven (40 ºC). Three of  
 
these bottles were used for the HPLC assay, one bottle was 
used for pH and macroscopic analyses and the last one for the 
microbiological assay.  
 
Microbiological Assay 
Samples were sent to an outsourced lab (GRAM - Laboratório 
de Análises Microbiológicas Ltda) at 0 and 21 days of 
storage. An assay for Pseudomonas aeruginosa, 
Staphylococcus aureus, Escherichia coli and Salmonella spp. 
was performed by the Cultural Method described in the 
Bacteriological Analytical Manual (2001) - Food and Drug 
Administration. Counts of total aerobic bacteria and total 
molds and yeasts were performed using the Pour Plate 
method described in Farmacopeia Brasileira, 5th Edition. 
 
Results and Discussion 
 
Formulation Development 
Formulation 1, which consisted of fluconazole incorporated 
into syrup, developed aggregates after manipulation. 
Levigating the drug with glycerin prior to the incorporation 
in Formulation 2 solved that problem. When using propylene 
glycol to replace glycerin in Formulation 3, levigation proved 
to be difficult and inefficient. The use of a 1% aqueous 
solution of carboxymethylcellulose (CMC) as a vehicle 
instead of syrup (Formulation 4) impaired fluconazole 
incorporation due to high viscosity, which led to the 
development of lumps in the formulation. Different quantities 
of 1% CMC solution were then tested (Formulations 5, 6 and 
7). All of them were easily prepared and demonstrated good 
appearance, free of lumps or air bubbles. 
  
pH and Viscosity 
Table 2 describes the pH and viscosity results obtained for the 
seven formulations tested. Formulation 2 had the lowest pH 
value of 5.78, and the highest recorded value was 6.82 for 
Formulation 4. The viscosity analysis indicated that 
formulations containing only simple syrup as a vehicle were 
the most fluid. The viscosity and torque values increase as the 
amount of CMC in the formulation increases. It is desirable 
that suspensions have a suitable viscosity to keep solid 
particles dispersed, ensuring homogeneity and dose 
uniformity. On the other hand, very viscous formulations 
should be avoided when it comes to the administration of the 
drug, as drug dispersion becomes difficult and the product can 
be partially retained in measuring cups, syringes and tubes15. 
 
Table 2 - pH, viscosity and torque values for the formulations 
manipulated. 
Formulation pH 1 Viscosity (cP) Torque (%) 
1 6.24 (±0.04) 259 13.0 
2 5.78 (±0.02) 356 13.9 
4 6.82 (±0.07) 1437 71.8 
5 6.36 (±0.03) 1024 51.2 
6 6.18 (±0.03) 906 45.5 
7 6.30 (±0.13) 422 19.3 
1 Mean and standard deviation for triplicates. 
 
 
 
Eq (1) 
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Volume of Sedimentation 
Table 3 describes the results obtained for the sedimentation 
volume for the seven formulations tested. Formulations 1 and 
2, which only had simple syrup as a vehicle, presented the 
highest sediment volumes and the highest sedimentation 
speeds. The inclusion of CMC in the formulations delayed 
this process. The use of a mixture of simple syrup and CMC 
as a vehicle proved to be more promising in Formulations 5, 
6 and 7, with minimal sedimentation over 7 days. The volume 
of sedimentation obtained was proportionally higher to the 
quantity of CMC in the formulation. 
 
Stokes' Law dictates that a particle rate of sedimentation is 
directly proportional to its diameter and inversely 
proportional to the medium viscosity 14. Grinding the drug 
prior to manipulation aims to reduce and normalize its 
particle size, leaving the medium viscosity as the only 
variable that affects sedimentation. The results obtained from 
the viscosity corroborate those from sedimentation volume, 
since the volumes tend to be proportionally higher to the 
viscosity of the formulations.   
 
Table 3 - Sedimentation volume calculated through the 
sediment volumes formed in each formulation over a 7-day 
follow-up. 
Volume of Sedimentation 
Time 
Formulation 
1 2 4 5 6 7 
0h 1.00 1.00 1.00 1.00 1.00 1.00 
1h 1.00 1.00 1.00 1.00 1.00 1.00 
2h 1.00 1.00 0.98 1.00 1.00 1.00 
24h 0.29 0.78 0.94 0.97 0.97 0.97 
48h 0.29 0.66 0.89 0.97 0.95 0.94 
72h 0.29 0.58 0.84 0.97 0.94 0.91 
168h 0.29 0.50 0.60 0.94 0.87 0.85 
 
 
Stability Study 
A pH close to neutrality was sought in formulations tested 
since this is more desirable for oral administration and 
because fluconazole degradation products were previously 
detected at extreme pH values6. A high viscosity value was 
not desired because it would make the administration with 
syringes and tubes difficult. The formulation also needs to 
keep its particles in suspension for as long as possible, 
ensuring the particles would not tend to compact, making the 
redispersion process easier. Thus, Formulations 6 and 7 were 
selected to continue the stability study. 
 
The formulation quantification assay results performed over 
14 days under different storage conditions are shown in Table 
4. The profiles can be analyzed in Figure 1. Fluconazole 
content was depleted by 8.5%, 12.5% and 11.5% in 
Formulation 6 at the end of 14 days when stored at room 
temperature, under refrigeration and in an oven at 40 ºC, 
respectively. In Formulation 7, the reduction of content was 
3.4% for room temperature storage, 5.6% under refrigeration 
and 6.5% for oven storage. Both formulations remained 
above 90% of content during the stability study. After 14 
days, Formulation 6 presented equivalent results when stored 
under refrigeration and in an oven, since there is no 
statistically significant difference between these conditions 
(P> 0.05). When stored at room temperature, a smaller loss of 
content was observed, indicating greater stability. When 
Formulation 7 is stored in an oven, an increase in content is 
noticed between days 7 and 14. This may be due to loss of 
water by evaporation, resulting in formulation concentration. 
   
The pH of the formulations was also evaluated along with the 
assay. Table 5 shows the pH values over time. Although both 
formulations have differences in composition and have been 
subjected to three storage temperatures, the pH presented 
little variation in all samples, remaining stable throughout the 
study. Both formulations showed the same profile in all cases, 
with a small drop in pH on the 7th day, returning to values 
close to the original on the 14th day.  
 
Figure 1 – Graphical representation of assay results in the 
stability study for Formulations 6 (a) and 7 (b). In black, 
bottles stored at room temperature. In blue, bottles stored 
under refrigeration (2 - 8 ºC). In red, bottles stored in an oven 
(40 ºC). 
 
 
Throughout the study, Formulation 6 showed no change in 
organoleptic properties. However, Formulation 7 showed a 
slightly darker color and phase separation under all storage 
conditions on the 14th day of stability (Figure 2). Since the 
only difference between the formulations is CMC proportion, 
it is assumed that the quantity used in Formulation 7 was 
insufficient to keep fluconazole in suspension, causing phase 
separation. Therefore, formulation 7 is not recommended for 
use due to the results obtained during the stability study. 
 
Both formulations presented absence of pathogens used in 
control and low aerobic bacteria, molds and total yeasts 
counts under all storage conditions after 0 and 21 days of 
manipulation. The evaluation of microbiological stability is 
used to determine a safe interval for product consumption, 
demonstrating storage conditions and product ability to avoid 
harmful effects from microbial contamination 9 
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Table 4 – Formulation assay results throughout 14 days of 
stability study when stored at room temperature, under 
refrigeration (2 ºC – 8 ºC) and in an oven (40 ºC). 
  
Room 
Temperature 
Refrigeration Oven 
   
 Day 
Assay 
(%) 
RSD 
(%) 
Assay 
(%) 
RSD 
(%) 
Assay 
(%) 
RSD 
(%) 
   
Formulation 
6 
0 102.6 1.9 102.6 1.9 102.6 1.9    
7 97.4 3.8 93.5 0.8 91.7 3.7    
14 94.1 2.8 90.1 3.1 91.1 1.7    
Formulation 
7 
0 103.3 5.9 103.3 5.9 103.3 5.9    
7 103.6 2.1 101.3 1.0 94.5 4.8    
14 99.9 6.0 97.7 8.4 96.8 5.4    
 
 
Table 5 – Formulation pH results throughout 14 days of 
stability study when stored at room temperature, under 
refrigeration (2 ºC – 8 ºC) and in an oven (40 ºC). 
pH 
 Day 
Room 
Temperature 
Refrigeration Oven 
Formulation 
6 
0 5.42 5.47 5.45 
7 4.55 4.57 4.34 
14 5.42 5.70 5.30 
Formulation 
7 
0 5.45 5.47 5.42 
7 4.58 4.54 4.28 
14 5.66 5.84 5.42 
 
. 
 
 
Figure 2 – Phase separation observed after 14 days of 
stability in Formulation 7 (right graduated cylinder). 
Formulation 6 after 14 days of stability for comparison (left 
graduated cylinder). 
 
 
Analytical Method Suitability 
Selectivity: Figure 3 shows Formulation 6 and placebo 
chromatograms. No interfering peak is observed in 
fluconazole retention time (3.491 min). 
 
Linearity: Linear regression obtained provided the equation y 
= 4.2113x - 26.105 and a 0.9972 coefficient of determination 
(r2). Residue analysis demonstrated homoscedasticity, 
absence of outlier points and absence of trend in their 
variances, demonstrating a random distribution. 
  
Precision: Based on criteria from the Association of Official 
Analytical Chemists (AOAC), the minimum relative standard 
deviation (RSD) required is 2.7% for repeatability and 4% for 
intermediate precision. In the present study, the RSD obtained 
were 0.54% and 1.46% respectively. 
   
 
 
Figure 3 – Formulation 6 (a) and Placebo (b) 
chromatograms. Mobile phase composed of acetonitrile and 
monobasic potassium phosphate buffer 20 mM pH 2.5 
(80:20) at isocratic flow rate of 1.5 mL / min, injection volume 
of 50 μL, room temperature, UV detector at 260 nm, Zorbax 
Eclipse column Plus C18 Agilent® (150 mm x 4.6 mm x 5 
μm). 
 
Accuracy: Based on criteria of the Association of Official 
Analytical Chemists (AOAC), recovery should be in the 
range of 97% to 103%. Table 6 shows recovery obtained and 
demonstrates method accuracy. 
 
Table 6 – Standard solution recoveries from samples 
obtained during analytical method accuracy. 
Accuracy 
Level 
(%) 
Fluconazole 
Concentration 
(µg/mL) 
Standard 
Added (µg) 
Mean Recovery 
(%) 
100 100 200 99.77 
110 110 300 102.64 
120 120 400 100.20 
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Conclusion 
 
It was possible to develop and characterize a liquid 
formulation for oral use in pharmaceutical suspension form 
containing fluconazole suitable for hospital use. It was also 
possible to demonstrate the suitability for a compendial assay 
method for the developed formulation. 
 
Formulation 6 was the most appropriate for hospital use and 
its results suggest incorporation of the suspension into 
the Farmacia Semi-Industrial portfolio, with a recommended 
shelf life of 14 days, stored in amber PET bottles and at room 
temperature. 
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